Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Jonathan D. Edgeworth; Domenico Merante; Sanjay Patel; Christopher Young; Paul Jones; Seema Vithlani; Duncan Wyncoll; Peter Roberts; Andrew Jones; Tsutae Den Nagata; Mari Ariyasu; David M. Livermore; Richard Beale

doi:10.1093/cid/ciy963

King's College London

King's main site

Research portal

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Research output: Contribution to journal › Article › peer-review

Jonathan D. Edgeworth, Domenico Merante, Sanjay Patel, Christopher Young, Paul Jones, Seema Vithlani, Duncan Wyncoll, Peter Roberts, Andrew Jones, Tsutae Den Nagata, Mari Ariyasu, David M. Livermore, Richard Beale

Original language	English
Pages (from-to)	1932-1934
Number of pages	3
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	68
Issue number	11
DOIs	https://doi.org/10.1093/cid/ciy963
Accepted/In press	8 Nov 2018
Published	12 Dec 2018
Additional links	Link to publication in Scopus

King's Authors

Abstract

Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase-positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.

View graph of relations

King's College London - Homepage

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

King's Authors

Abstract

By the same authors

With some of the same researchers

From the same journal